Exacerbation of diabetic nephropathy by Hyperlipidaemia is mediated by Toll-like receptor 4 in mice

Diabetologia

Volumn 55, Issue 8, 2012, Pages 2256-2266

  Kuwabara, T ^a   Mori, K ^a   Mukoyama, M ^a   Kasahara, M ^a   Yokoi, H ^a   Saito, Y ^a   Ogawa, Y ^b   Imamaki, H ^a   Kawanishi, T ^a   Ishii, A ^a   Koga, K ^a   Mori, K P ^a   Kato, Y ^a   Sugawara, A ^b   Nakao, K ^a  

^a KYOTO UNIVERSITY   (Japan)

^b OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

Diabetic nephropathy; Glomerulus; High fat diet; Hyperlipidaemia; Macrophages; S100A8; TLR4

Indexed keywords

CALGRANULIN A; INTERFERON REGULATORY FACTOR 3; STREPTOZOCIN; TOLL LIKE RECEPTOR 4;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELL INFILTRATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE EXACERBATION; GENE EXPRESSION REGULATION; GLOMERULUS; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; KIDNEY HYPERTROPHY; KIDNEY INJURY; KNOCKOUT MOUSE; LIPID DIET; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; UPREGULATION; WILD TYPE;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; HYPERLIPIDEMIAS; KIDNEY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STREPTOZOCIN; TOLL-LIKE RECEPTOR 4;

EID: 84866381264     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2578-1     Document Type: Review

References (47)

1. Maisonneuve P, Agodoa L, Gellert R et al (2000) Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis 35:157-165
2. Decleves AE, Sharma K (2010) New pharmacological treatments for improving renal outcomes in diabetes. Nat Rev Nephrol 6:371-380
3. El-Atat FA, Stas SN, McFarlane SI, Sowers JR (2004) The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol 15:2816-2827
4. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS (2003) Regression of microalbuminuria in type 1 diabetes. N Engl J Med 348:2285-2293
5. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R (1998) Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 158:998-1004
6. Rutledge JC, Ng KF, Aung HH, Wilson DW (2010) Role of triglyceride-rich lipoproteins in diabetic nephropathy. Nat Rev Nephrol 6:361-370
7. Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4:499-511
8. Brown HJ, Lock HR, Wolfs TG, Buurman WA, Sacks SH, Robson MG (2007) Toll-like receptor 4 ligation on intrinsic renal cells contributes to the induction of antibody-mediated glomerulonephritis via CXCL1 and CXCL2. J Am Soc Nephrol 18:1732-1739
9. Wu H, Chen G, Wyburn KR et al (2007) TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest 117:2847-2859
10. Zhang B, Ramesh G, Uematsu S, Akira S, Reeves WB (2008) TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. J Am Soc Nephrol 19:923-932
11. Liu B, Yang Y, Dai J et al (2006) TLR4 up-regulation at protein or gene level is pathogenic for lupus-like autoimmune disease. J Immunol 177:6880-6888
12. Kruger B, Krick S, Dhillon N et al (2009) Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci USA 106:3390-3395
13. Lin M, Yiu WH, Wu HJ et al (2012) Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J Am Soc Nephrol 23:86-102
14. Hoshino K, Takeuchi O, Kawai T et al (1999) Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 162:3749-3752
15. Kuwabara T, Mori K, Mukoyama M et al (2009) Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney Int 75:285-294
16. Kusakabe T, Tanioka H, Ebihara K et al (2009) Beneficial effects of leptin on glycaemic and lipid control in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and a high-fat diet. Diabetologia 52:675-683
17. Jung K, Wesslau C, Priem F, Schreiber G, Zubek A (1987) Specific creatinine determination in laboratory animals using the new enzymatic test kit "Creatinine-PAP". J Clin Chem Clin Biochem 25:357-361
18. Suganami T, Mukoyama M, Sugawara A et al (2001) Overexpression of brain natriuretic peptide in mice ameliorates immunemediated renal injury. J Am Soc Nephrol 12:2652-2663
19. Yokoi H, Mukoyama M, Mori K et al (2008) Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice. Kidney Int 73:446-455
20. Suganami T, Mukoyama M, Mori K (2005) Prevention and reversal of renal injury by leptin in a new mouse model of diabetic nephropathy. FASEB J 19:127-129
21. Suganami T, Yuan X, Shimoda Y et al (2009) Activating transcription factor 3 constitutes a negative feedback mechanism that attenuates saturated Fatty acid/toll-like receptor 4 signaling and macrophage activation in obese adipose tissue. Circ Res 105:25-32
22. Qi Z, Fujita H, Jin J et al (2005) Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 54:2628-2637
23. Vaisse C, Halaas JL, Horvath CM, Darnell JE Jr, Stoffel M, Friedman JM (1996) Leptin activation of Stat3 in the hypothalamus of wildtype and ob/ob mice but not db/db mice. Nat Genet 14:95-97
24. Vogl T, Tenbrock K, Ludwig S et al (2007) Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 13:1042-1049
25. Suganami T, Mieda T, Itoh M, Shimoda Y, Kamei Y, Ogawa Y (2007) Attenuation of obesity-induced adipose tissue inflammation in C3H/HeJ mice carrying a Toll-like receptor 4 mutation. Biochem Biophys Res Commun 354:45-49
26. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS (2006) TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116:3015-3025
27. Xu XH, Shah PK, Faure E et al (2001) Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 104:3103-3108
28. Kume S, Uzu T, Araki S et al (2007) Role of altered renal lipid metabolism in the development of renal injury induced by a highfat diet. J Am Soc Nephrol 18:2715-2723
29. Okamura DM, Pennathur S, Pasichnyk K et al (2009) CD36 regulates oxidative stress and inflammation in hypercholesterolemic CKD. J Am Soc Nephrol 20:495-505
30. Jiang T, Wang Z, Proctor G et al (2005) Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. J Biol Chem 280:32317-32325
31. Croce K, Gao H, Wang Y et al (2009) Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation 120:427-436
32. Loser K, Vogl T, Voskort M et al (2010) The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat Med 16:713-717
33. Burkhardt K, Schwarz S, Pan C et al (2009) Myeloid-related protein 8/14 complex describes microcirculatory alterations in patients with type 2 diabetes and nephropathy. Cardiovasc Diabetol 8:10
34. Bouma G, Lam-Tse WK, Wierenga-Wolf AF, Drexhage HA, Versnel MA (2004) Increased serum levels of MRP-8/14 in type 1 diabetes induce an increased expression of CD11b and an enhanced adhesion of circulating monocytes to fibronectin. Diabetes 53:1979-1986
35. Yamamoto Y, Kato I, Doi T et al (2001) Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108:261-268
36. Furuta T, Saito T, Ootaka T et al (1993) The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 21:480-485
37. Sassy-Prigent C, Heudes D, Mandet C et al (2000) Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 49:466-475
38. Usui HK, Shikata K, Sasaki M et al (2007) Macrophage scavenger receptor-a-deficient mice are resistant against diabetic nephropathy through amelioration of microinflammation. Diabetes 56:363-372
39. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH (2006) Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 69:73-80
40. Chow FY, Nikolic-Paterson DJ, Ma FY, Ozols E, Rollins BJ, Tesch GH (2007) Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia 50:471-480
41. Kanamori H, Matsubara T, Mima A et al (2007) Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun 360:772-777
42. Sayyed SG, Ryu M, Kulkarni OP et al (2011) An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes. Kidney Int 80:68-78
43. Yokoi H, Mukoyama M, Sugawara A et al (2002) Role of connective tissue growth factor in fibronectin expression and tubulointerstitial fibrosis. Am J Physiol Renal Physiol 282:F933-942
44. Takano Y, Yamauchi K, Hayakawa K et al (2007) Transcriptional suppression of nephrin in podocytes by macrophages: roles of inflammatory cytokines and involvement of the PI3K/Akt pathway. FEBS Lett 581:421-426
45. Lee EY, Chung CH, Khoury CC et al (2009) The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF-beta, increases podocyte motility and albumin permeability. Am J Physiol Renal Physiol 297:F85-94
46. Kwoh C, Shannon MB, Miner JH, Shaw A (2006) Pathogenesis of nonimmune glomerulopathies. Annu Rev Pathol 1:349-374
47. Kagan JC, Su T, Horng T, Chow A, Akira S, Medzhitov R (2008) TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat Immunol 9:361-368